DOCSLIB.ORG

Rad51 As Functional Biomarker to Select Tumors for Parp Inhibitor Treatment

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Rad51 As Functional Biomarker to Select Tumors for Parp Inhibitor Treatment ADVERTIMENT. Lʼaccés als continguts dʼaquesta tesi queda condicionat a lʼacceptació de les condicions dʼús establertes per la següent llicència Creative Commons: http://cat.creativecommons.org/?page_id=184 ADVERTENCIA. El acceso a los contenidos de esta tesis queda condicionado a la aceptación de las condiciones de uso establecidas por la siguiente licencia Creative Commons: http://es.creativecommons.org/blog/licencias/ WARNING. The access to the contents of this doctoral thesis it is limited to the acceptance of the use conditions set by the following Creative Commons license: https://creativecommons.org/licenses/?lang=en RAD51 AS FUNCTIONAL BIOMARKER TO SELECT TUMORS FOR PARP INHIBITOR TREATMENT JF1"3,2%-,*%-+0)02-1*223+-01 "-0%,$%%2-0202+,2 02120-4%(-0+(- ?6#8)0#1:/(#86#;:) 983;6 //"U #831 19:):;:#3&1 3/3'@_ ` )8# :38R8S)3/#:#88/)A/"#1"8S#8 $8:*)63// ;:38R8S 39%)';#/ )A 13"##' (683'80)1)3 (#0)9:8@P3/# ;/8)3/3'@1")30#") )1# #68:0#1:3&)3 (#0)9:8@1"3/# ;/8)3/3'@ 1)=#89)"";:4130"#8 #/31_` 8 #/31Pnlmu (#")8# :3890=%-*200*%8*1"0=0 02&%.-**1":(# :;:380= -1!%#3* %8,-#P #8:)&@R (::(##?6#8)0#1:/>38.1":(#>8):)1'3&:(#0#038@3&:()9"3 :38/ :(#9)9 #1:):/#" Vqm 9 &;1 :)31/ )308.#8 :3 9#/# : :;0389 &38 )1()):38 :8#:0#1:W (=# ##1 6#8&380#" @ 8: 9:83=)#-3 #80#-3 ;1"#8:(#)89;6#8=)9)311" 319)"#8:(:):)99;):/#:3#68#9#1:#"&38:(# "#'8##3&3 :383&()/3936(@_(`)1)3 (#0)9:8@P3/# ;/8)3/3'@1" )30#") )1#@1)=#89)"";:4130"#8 #/31 8 #/31Pnlmu (1")":# 02120-4%(-0+(- )8# :389 ;:38 0=%-*200*%8*1"0=0 02&%.-** 0= -1!%#3* %8,-# &.")() ACKNOWLEDGEMENTS # *#>:317;#6;"30)88:1/#-396387;#9#;64(30839"#')'1:#9S3#9 8)3 (3@#9:9/*1#968"#-87;*P#16</) 3P/391308#9"#:3"397;#//397;#P"#;1; 3:801#8P0#(1 #")"39;9(30839";81:##9:# 0)1368( #8/3639)/#S )68)0#8'8"# )0)#1:3#968/';)#1:1#96# )/7;# ;/7;)#86/8"#'8:):;" 9#7;#" 38:R%P 317;)#1 3068:3/390)#"39@/9/#'8*9P/968#3 ;6 )31#9@ /9 #8:#A9S38:;6 )#1 )P)1:#/)'#1 )@'#1#839)""S38 3068#1"#80#9)#068#@ 3068:)8 310)'3:3"9/9()9:38)97;#=)=3P6)#193@=# #9)1 /;939;#23P:0)%1/ "#1;#9:8=)"S 0).0P6389#89)#068#0)0#9:83@';*#1/ )#1 )"#//0S0)+0P6389#8 #-#06/3"#:#1 )""P=/#1:*@9;6#8 )41S0)$0+,P6387;#7;)A9/368)0#837;# 0##19#29:#&;#/##8P6#83#939#2"#;1/8'/)9:#1 31:)1;3 8# )0)#1:3P"#/ 7;#"#9: 8*:;#1380##06:*@'#1#839)""S/39:8#9P-;1:39P63883"#80#9)#068#P 303#/397;#;183/P@:80#/9;#/3)1 /;93 ;1"3936/#/=)#1:3S38( #80# 3068#1"#87;#13:#1'3#1#/0;1"33:83"##87;#//#'8*S :3"0)"+%*%P9:83=)#-39P#80#-39P3"8*';#A@V6#'"39WP638 31&)8#10*09 7;#@30)90P"#9"#)#16#7;#2):P@13"#-8"#( #8/31;1 S:3"39/397;##9:)9@ /397;#&/:1P ;@3(;# 3#9)0639)/#//#18P6#837;#"#-1693/)/;9)41"#/397;# //#'1 1;#=39S 387;# 13 (# 63")"3 698 :3"3 #/ :)#063 7;# 7;)9)#8 31 =393:839 ";81:##9:=38')1#683&#9)31/P6#83P<1#9:1"3/#-39P9)#068##9:)968#9#1:#9#1 0)9=/38#9@#1 " :3P#1 ""# )9)41")8)7;#:303S 36;#"3"#-8"#"8;1'8 )9/8'3@#?:#193P 303/9(3897;#(#039 3068:)"3P 0)9 3062#839"#//38:38)3"##86)9?6#8)0#1:/#9S02%1P638:;69)41( ) /37;#( #9@#/)06;/93 8#:)=3"#:;'#1)/(;038S*02P638 3'#80# 31:1:3 8)23_6#98"#9#8"# 3'8323`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`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ml INDEX mn ==============================================================================================================================N ======================================================================================================================================================FF ======================================================================================================================================FL ===============================================================================================================================================GJ ================================================================================================================================================GN =======================================================================================================================================HH mS SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSoq ),'&&&3&888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888BD 3&&/&,*,)---,&0(.),(,8888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888BD nS SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSpm )')&))/-,)'!(.!)(,*!,88888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888CA @)'!(-(!(!(*,.(,-8888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888CC oS SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSps ,'&!(888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888CF pS SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSpu (!-'-)!,-!-.(888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888DA !3)(88888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888DG qS SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSqu &.!(/'-(-!.!0!.388888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888DH !)',%,--)(('/..!)((&3-!-8888888888888888888888888888888888888888888888888888888888888888888888888888888888888888E? ()'!-,-('/..!)(&-!(./,-888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888E@ 3('!!)',%,-8888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888EB . ,!)',%,-88888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888EC rS SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSrr )'!(.!)(1!. !( !!.),-88888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888EE =================================================================================================================LF 3*). -!-@8888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888FB 3*). -!-A8888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888FB 3*). -!-B8888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888FC 3*). -!-C8888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888888FC ===============================================================================================================================================LJ
Load more

Recommended publications
  • What Is Fanconi Anemia and How Is It Diagnosed
    Fanconi anemia and its diagnosis: Fanconi anemia (FA), named for the Swiss pediatrician Guido Fanconi, is an inherited disorder that can lead to bone marrow failure (aplastic anemia), leukemia and/or solid tumors, with oral and gynecologic tumors being the most common. FA is almost exclusively a recessive disorder: if both parents carry a defect (mutation) in the same FA gene, each of their children has a 25% chance of inheriting the defective gene from both parents. When this happens, the child will have FA. While the total number of FA patients is not documented worldwide, scientists estimate that the carrier frequency (carriers are people carrying a defect in one copy of a particular FA gene, whose other copy of that same FA gene is normal) for FA in the U.S. is 1 in 181. The incidence rate, or the likelihood of a child being born with FA, is about 1 in 131,000 in the U.S., with approximately 31 babies born with FA each year. Scientists have now discovered 19 FA genes [FANCA, -B, -C, -D1 (also known as BRCA2), D2, E, F, G, I, J, L, M, N, O, P, Q, RAD51, BRCA1, and T]. Mutations in these genes account for more than 95% of reported Fanconi anemia cases. Mutations in FANCA, FANCC and FANCG are the most common and account for approximately 85% of FA patients worldwide. FANCD1, FANCD2, FANCE, FANCF and FANCL account for 10%, while the remaining FA genes, FANCB, FANCI, FANCJ, FANCM, FANCN, FANCO, FANCP, and FANCQ represent less than 5%. Some individuals with FA do not appear to have mutations in these 19 genes, so we anticipate that additional FA genes will be discovered in the future.
    [Show full text]
  • Open Full Page
    CCR PEDIATRIC ONCOLOGY SERIES CCR Pediatric Oncology Series Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders Michael F. Walsh1, Vivian Y. Chang2, Wendy K. Kohlmann3, Hamish S. Scott4, Christopher Cunniff5, Franck Bourdeaut6, Jan J. Molenaar7, Christopher C. Porter8, John T. Sandlund9, Sharon E. Plon10, Lisa L. Wang10, and Sharon A. Savage11 Abstract DNA repair syndromes are heterogeneous disorders caused by around the world to discuss and develop cancer surveillance pathogenic variants in genes encoding proteins key in DNA guidelines for children with cancer-prone disorders. Herein, replication and/or the cellular response to DNA damage. The we focus on the more common of the rare DNA repair dis- majority of these syndromes are inherited in an autosomal- orders: ataxia telangiectasia, Bloom syndrome, Fanconi ane- recessive manner, but autosomal-dominant and X-linked reces- mia, dyskeratosis congenita, Nijmegen breakage syndrome, sive disorders also exist. The clinical features of patients with DNA Rothmund–Thomson syndrome, and Xeroderma pigmento- repair syndromes are highly varied and dependent on the under- sum. Dedicated syndrome registries and a combination of lying genetic cause. Notably, all patients have elevated risks of basic science and clinical research have led to important in- syndrome-associated cancers, and many of these cancers present sights into the underlying biology of these disorders. Given the in childhood. Although it is clear that the risk of cancer is rarity of these disorders, it is recommended that centralized increased, there are limited data defining the true incidence of centers of excellence be involved directly or through consulta- cancer and almost no evidence-based approaches to cancer tion in caring for patients with heritable DNA repair syn- surveillance in patients with DNA repair disorders.
    [Show full text]
  • Predictive Value of RAD51 on the Survival and Drug Responsiveness of Ovarian Cancer Yuchen Feng1, Daoqi Wang2, Luyang Xiong3, Guohua Zhen1 and Jiahong Tan4*
    Feng et al. Cancer Cell Int (2021) 21:249 https://doi.org/10.1186/s12935-021-01953-5 Cancer Cell International PRIMARY RESEARCH Open Access Predictive value of RAD51 on the survival and drug responsiveness of ovarian cancer Yuchen Feng1, Daoqi Wang2, Luyang Xiong3, Guohua Zhen1 and Jiahong Tan4* Abstract Background: Ovarian cancer has greatly endangered and deteriorated female health conditions worldwide. Refne- ment of predictive biomarkers could enable patient stratifcation and help optimize disease management. Methods: RAD51 expression profle, target-disease associations, and ftness scores of RAD51 were analyzed in ovar- ian cancer using bioinformatic analysis. To further identify its role, gene enrichment analysis was performed, and a regulatory network was constructed. Survival analysis and drug sensitivity assay were performed to evaluate the efect of RAD51 expression on ovarian cancer prognosis. The predictive value of RAD51 was then confrmed in a validation cohort immunohistochemically. Results: Ovarian cancer expressed more RAD51 than normal ovary. RAD51 conferred ovarian cancer dependency and was associated with ovarian cancer. RAD51 had extensive target-disease associations with various diseases, including ovarian cancer. Genes that correlate with and interact with RAD51 were involved in DNA damage repair and drug responsiveness. High RAD51 expression indicated unfavorable survival outcomes and resistance to platinum, taxane, and PARP inhibitors in ovarian cancer. In the validation cohort (126 patients), high RAD51 expression indicated platinum resistance, and platinum-resistant patients expressed more RAD51. Patients with high RAD51 expression had shorter OS (HR 2.968, P < 0.0001) and poorer PFS (HR 2.838, P < 0.0001). RAD51 expression level was negatively cor- related with patients’= survival length.
    [Show full text]
  • The Bloom Syndrome Protein Limits the Lethality Associated with RAD51 Deficiency
    Published OnlineFirst March 9, 2010; DOI: 10.1158/1541-7786.MCR-09-0534 Molecular DNA Damage and Cellular Stress Responses Cancer Research The Bloom Syndrome Protein Limits the Lethality Associated with RAD51 Deficiency Kenza Lahkim Bennani-Belhaj1,2, Sébastien Rouzeau1,2, Géraldine Buhagiar-Labarchède1,2, Pauline Chabosseau1,2, Rosine Onclercq-Delic1,2, Emilie Bayart1, Fabrice Cordelières3,4, Jérôme Couturier5,6, and Mounira Amor-Guéret1,2 Abstract Little is known about the functional interaction between the Bloom's syndrome protein (BLM) and the re- combinase RAD51 within cells. Using RNA interference technology, we provide the first demonstration that RAD51 acts upstream from BLM to prevent anaphase bridge formation. RAD51 downregulation was associated with an increase in the frequency of BLM-positive anaphase bridges, but not of BLM-associated ultrafine bridges. Time-lapse live microscopy analysis of anaphase bridge cells revealed that BLM promoted cell survival in the absence of Rad51. Our results directly implicate BLM in limiting the lethality associated with RAD51 deficiency through the processing of anaphase bridges resulting from the RAD51 defect. These findings provide insight into the molecular basis of some cancers possibly associated with variants of the RAD51 gene family. Mol Cancer Res; 8(3); 385–94. ©2010 AACR. Introduction cently, SUMOylation of BLM has been shown to regulate its association with RAD51 and its function in HR-medi- Bloom's syndrome displays one of the strongest known ated repair of damaged replication forks (13). In several correlations between chromosomal instability and a high models, it has been proposed that BLM restarts replication risk of cancer at an early age.
    [Show full text]
  • FANCJ Regulates the Stability of FANCD2/FANCI Proteins and Protects Them from Proteasome and Caspase-3 Dependent Degradation
    FANCJ regulates the stability of FANCD2/FANCI proteins and protects them from proteasome and caspase-3 dependent degradation Komaraiah Palle, Ph.D. (Kumar) Assistant Professor of Oncologic Sciences Abraham Mitchell Cancer Research Scholar Mitchell Cancer Institute University of South Alabama Outline • Fanconi anemia (FA) pathway • Role of FA pathway in Genome maintenance • FANCJ and FANCD2 functional relationship • FANCJ-mediated DDR in response to Fork-stalling Fanconi Anemia • Rare, inherited blood disorder. • 1:130,000 births Guido Fanconi 1892-1979 • Affects men and women equally. • Affects all racial and ethnic groups – higher incidence in Ashkenazi Jews and Afrikaners Birth Defects Fanconi anemia pathway • FA is a rare chromosome instability syndrome • Autosomal recessive disorder (or X-linked) • Developmental abnormalities • 17 complementation groups identified to date • FA pathway is involved in DNA repair • Increased cancer susceptibility - many patients develop AML - in adults solid tumors Fanconi Anemia is an aplastic anemia FA patients are prone to multiple types of solid tumors • Increased incidence and earlier onset cancers: oral cavity, GI and genital and reproductive tract head and neck breast esophagus skin liver brain Why? FA is a DNA repair disorder • FA caused by mutations in 17 genes: FANCA FANCF FANCM FANCB FANCG/XRCC9 FANCN/PALB2 FANCC FANCI RAD51C/FANCO FANCD1/BRCA2 FANCJ SLX4/FANCP FANCD2 FANCL ERCC2/XPF/FANCQ FANCE BRCA1/FANCS • FA genes function in DNA repair processes • FA patient cells are highly sensitive
    [Show full text]
  • Mutations in the RAD54 Recombination Gene in Primary Cancers
    Oncogene (1999) 18, 3427 ± 3430 ã 1999 Stockton Press All rights reserved 0950 ± 9232/99 $12.00 http://www.stockton-press.co.uk/onc SHORT REPORT Mutations in the RAD54 recombination gene in primary cancers Masahiro Matsuda1,4, Kiyoshi Miyagawa*,1,2, Mamoru Takahashi2,4, Toshikatsu Fukuda1,4, Tsuyoshi Kataoka4, Toshimasa Asahara4, Hiroki Inui5, Masahiro Watatani5, Masayuki Yasutomi5, Nanao Kamada3, Kiyohiko Dohi4 and Kenji Kamiya2 1Department of Molecular Pathology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Hiroshima 734, Japan; 2Department of Developmental Biology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Hiroshima 734, Japan; 3Department of Cancer Cytogenetics, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Hiroshima 734, Japan; 42nd Department of Surgery, Hiroshima University School of Medicine, 1-2-3 Kasumi, Minami-ku, Hiroshima 734, Japan; 51st Department of Surgery, Kinki University School of Medicine, 377-2 Ohno-higashi, Osaka-sayama, Osaka 589, Japan Association of a recombinational repair protein RAD51 therefore, probable that members of the RAD52 with tumor suppressors BRCA1 and BRCA2 suggests epistasis group are altered in cancer. that defects in homologous recombination are responsible To investigate whether RAD54, a member of the for tumor formation. Also recent ®ndings that a protein RAD52 epistasis group, is mutated in human cancer, associated with the MRE11/RAD50 repair complex is we performed SSCP analysis and direct sequencing of mutated in Nijmegen breakage syndrome characterized PCR products using mRNAs from 132 unselected by increased cancer incidence and ionizing radiation primary tumors including 95 breast cancers, 13 sensitivity strongly support this idea.
    [Show full text]
  • Fanconi Anemia, Bloom Syndrome and Breast Cancer
    A multiprotein complex in DNA damage response network of Fanconi anemia, Bloom syndrome and Breast cancer Weidong Wang Lab of Genetics, NIA A Multi-protein Complex Connects Two Genomic Instability Diseases: Bloom Syndrome and Fanconi Anemia Bloom Syndrome . Genomic Instability: -sister-chromatid exchange . Cancer predisposition . Mutation in BLM, a RecQ DNA Helicase . BLM participates in: HR-dependent DSB repair Recovery of stalled replication forks . BLM works with Topo IIIa and RMI to Suppress crossover recombination Courtesy of Dr. Ian Hickson A Multi-protein Complex Connects Two Genomic Instability Diseases: Bloom Syndrome and Fanconi Anemia P I l o r t n o BLM IP kDa C HeLa BLAP 250 Nuclear Extract 200- BLM* FANCA* 116- TOPO IIIα* 97- BLAP 100 MLH1* BLM IP BLAP 75 * 66- RPA 70 IgG H 45- * 30- RPA32 IgG L 20- * 12- RPA14 Meetei et al. MCB 2003 A Multi-protein Complex Connects Two Genomic Instability Diseases: Bloom Syndrome and Fanconi Anemia P I A C N A F BLM IP HeLa FANCM= FAAP 250 BLAP 250 Nuclear Extract BLM* BLM* * FANCA* FANCA TOPO IIIα* TOPO IIIα* FAAP 100 BLAP 100 FANCB= FAAP 95 MLH1 FANCA IP BLM IP BLAP 75 BLAP 75 RPA70*/FANCG* RPA 70* FANCC*/FANCE* IgG H FANCL= FAAP 43 FANCF* RPA32* IgG L Meetei et al. MCB 2003 Meetei et al. Nat Genet. 2003, 2004, 2005 BRAFT-a Multisubunit Machine that Maintains Genome Stability and is defective in Fanconi anemia and Bloom syndrome BRAFT Super-complex Fanconi Anemia Bloom Syndrome Core Complex Complex 12 polypeptides 7 polypeptides FANCA BLM Helicase (HJ, fork, D-loop), fork FANCC regression, dHJ dissolution Topo IIIα Topoisomerase, FANCE dHJ dissolution FANCF BLAP75 RMI1 FANCG Stimulates dHJ dissolution.
    [Show full text]
  • HEREDITARY CANCER PANELS Part I
    Pathology and Laboratory Medicine Clinic Building, K6, Core Lab, E-655 2799 W. Grand Blvd. HEREDITARY CANCER PANELS Detroit, MI 48202 855.916.4DNA (4362) Part I- REQUISITION Required Patient Information Ordering Physician Information Name: _________________________________________________ Gender: M F Name: _____________________________________________________________ MRN: _________________________ DOB: _______MM / _______DD / _______YYYY Address: ___________________________________________________________ ICD10 Code(s): _________________/_________________/_________________ City: _______________________________ State: ________ Zip: __________ ICD-10 Codes are required for billing. When ordering tests for which reimbursement will be sought, order only those tests that are medically necessary for the diagnosis and treatment of the patient. Phone: _________________________ Fax: ___________________________ Billing & Collection Information NPI: _____________________________________ Patient Demographic/Billing/Insurance Form is required to be submitted with this form. Most genetic testing requires insurance prior authorization. Due to high insurance deductibles and member policy benefits, patients may elect to self-pay. Call for more information (855.916.4362) Bill Client or Institution Client Name: ______________________________________________________ Client Code/Number: _____________ Bill Insurance Prior authorization or reference number: __________________________________________ Patient Self-Pay Call for pricing and payment options Toll
    [Show full text]
  • Supplementary Table S1. Correlation Between the Mutant P53-Interacting Partners and PTTG3P, PTTG1 and PTTG2, Based on Data from Starbase V3.0 Database
    Supplementary Table S1. Correlation between the mutant p53-interacting partners and PTTG3P, PTTG1 and PTTG2, based on data from StarBase v3.0 database. PTTG3P PTTG1 PTTG2 Gene ID Coefficient-R p-value Coefficient-R p-value Coefficient-R p-value NF-YA ENSG00000001167 −0.077 8.59e-2 −0.210 2.09e-6 −0.122 6.23e-3 NF-YB ENSG00000120837 0.176 7.12e-5 0.227 2.82e-7 0.094 3.59e-2 NF-YC ENSG00000066136 0.124 5.45e-3 0.124 5.40e-3 0.051 2.51e-1 Sp1 ENSG00000185591 −0.014 7.50e-1 −0.201 5.82e-6 −0.072 1.07e-1 Ets-1 ENSG00000134954 −0.096 3.14e-2 −0.257 4.83e-9 0.034 4.46e-1 VDR ENSG00000111424 −0.091 4.10e-2 −0.216 1.03e-6 0.014 7.48e-1 SREBP-2 ENSG00000198911 −0.064 1.53e-1 −0.147 9.27e-4 −0.073 1.01e-1 TopBP1 ENSG00000163781 0.067 1.36e-1 0.051 2.57e-1 −0.020 6.57e-1 Pin1 ENSG00000127445 0.250 1.40e-8 0.571 9.56e-45 0.187 2.52e-5 MRE11 ENSG00000020922 0.063 1.56e-1 −0.007 8.81e-1 −0.024 5.93e-1 PML ENSG00000140464 0.072 1.05e-1 0.217 9.36e-7 0.166 1.85e-4 p63 ENSG00000073282 −0.120 7.04e-3 −0.283 1.08e-10 −0.198 7.71e-6 p73 ENSG00000078900 0.104 2.03e-2 0.258 4.67e-9 0.097 3.02e-2 Supplementary Table S2.
    [Show full text]
  • Scaffolding Protein SPIDR/KIAA0146 Connects the Bloom Syndrome Helicase with Homologous Recombination Repair
    Scaffolding protein SPIDR/KIAA0146 connects the Bloom syndrome helicase with homologous recombination repair Li Wan1, Jinhua Han1, Ting Liu1, Shunli Dong, Feng Xie, Hongxia Chen, and Jun Huang2 Life Sciences Institute, Zhejiang University, Hangzhou, Zhejiang 310058, China Edited by James E. Cleaver, University of California, San Francisco, CA, and approved February 26, 2013 (received for review December 1, 2012) The Bloom syndrome gene product, BLM, is a member of the highly of the SDSA pathway (6, 7). The ability of BLM to yield non- conserved RecQ family. An emerging concept is the BLM helicase crossover products is thought to play a critical role in the avoidance collaborates with the homologous recombination (HR) machinery to of chromosomal rearrangements during the homolog-directed re- help avoid undesirable HR events and to achieve a high degree of pair of chromosomal lesions. As a result, cells defective for BLM fidelity during the HR reaction. However, exactly how such coordina- exhibit elevated rates of sister chromatid exchange (SCE) (19–21). tion occurs in vivo is poorly understood. Here, we identified a protein Upon the occurrence of DNA damage, BLM is able to form termed SPIDR (scaffolding protein involved in DNA repair) as the link discrete foci, where it colocalizes with other DNA repair proteins between BLM and the HR machinery. SPIDR independently interacts (22, 23). However, mechanistically how BLM is recruited to sites with BLM and RAD51 and promotes the formation of a BLM/RAD51- of DNA damage and how it collaborates with other proteins to containing complex of biological importance. Consistent with its role mediate recombination repair remain largely unexplored.
    [Show full text]
  • Challenges in Reporting Pathogenic/Potentially
    www.nature.com/scientificreports OPEN Challenges in reporting pathogenic/ potentially pathogenic variants in 94 cancer predisposing genes - in pediatric patients screened with NGS panels Adela Chirita-Emandi 1,2,6*, Nicoleta Andreescu1,2,6, Cristian G. Zimbru1,3, Paul Tutac1,2, Smaranda Arghirescu4,5, Margit Serban5 & Maria Puiu1,2 The beneft of reporting unsolicited fndings in Next Generation Sequencing (NGS) related to cancer genes in children may have implications for family members, nevertheless, could also cause distress. We aimed to retrospectively investigate germline variants in 94 genes implicated in oncogenesis, in patients referred to NGS testing for various rare genetic diseases and reevaluate the utility of reporting diferent classes of pathogenicity. We used in silico prediction software to classify variants and conducted manual review to examine unsolicited fndings frequencies in 145 children with rare diseases, that underwent sequencing - using a 4813 gene panel. The anonymized reanalysis revealed 18250 variants, of which 126 were considered after fltering. Six pathogenic variants (in BRCA1,BMPR1A,FANCA,FANCC,NBN genes) with cancer related phenotype and three unsolicited variants (in BRCA2,PALB2,RAD50 genes) were reported to patients. Additionally, three unsolicited variants in ATR, BLM (in two individuals), and FANCB genes presented potential cancer susceptibility, were not reported to patients. In retrospect, 4.8% (7/145) of individuals in our cohort had unsolicited NGS fndings related to cancer. More eforts are needed to create an updatable consensus in reporting variants in cancer predisposing genes, especially for children. Consent process is crucial to inform of both value and risk of additional genetic information. Next-Generation Sequencing (NGS) for large panels of genes or exomes are increasingly and successfully used in medical management for rare diseases and cancer.
    [Show full text]
  • Neurodegeneration in Accelerated Aging
    DOCTOR OF MEDICAL SCIENCE DANISH MEDICAL JOURNAL Neurodegeneration in Accelerated Aging Morten Scheibye-Knudsen This review has been accepted as a thesis together with 7 previously published pa- pers by the University of Copenhagen, October 16, 2014 and defended on January 14, 2016 Official opponents: Alexander Bürkle, University of Konstanz Lars Eide, University of Oslo Correspondence: Center for Healthy Aging, Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen E-mail: [email protected] Dan Med J 2016;63(11):B5308 INTRODUCTION The global elderly population has been progressively increasing throughout the 20th century and this growth is projected to per- sist into the late 21st century resulting in 20% of the total world population being aged 65 or more by the year 2100 (Figure 1). 80% of the total cost of health care is accrued after 40 years of Figure 2. The phenotype of human aging. age where chronic diseases become prevalent [1, 2]. With an ex- that appear to regulate the aging process [4,5]. These include the ponential increase in health care costs, it follows that the chronic insulin and IGF-1 signaling cascades [4], protein synthesis and diseases that accumulate in an aging population poses a serious quality control [6], regulation of cell proliferation through factors socioeconomic problem. Finding treatments to age related dis- such as mTOR [7], stem cell maintenance 8 as well as mitochon- eases, therefore becomes increasingly more pertinent as the pop- drial preservation [9]. Most of these pathways are conserved ulation ages. Even more so since there appears to be a continu- through evolution and appear to regulate aging in many lower or- ous increase in the prevalence of chronic diseases in the aging ganisms.
    [Show full text]